Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
Overview
Authors
Affiliations
Introduction: Because nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver disease, noninvasive evaluations of its severity are immediately needed. This prospective cross-sectional study evaluated the effectiveness of noninvasive assessments of hepatic steatosis, fibrosis, and steatohepatitis.
Methods: Patients underwent laboratory tests, liver biopsy, transient elastography, and MRI. Multiparametric MR was used to measure MRI proton density fat fraction, MR spectroscopy, T1 mapping, and MR elastography (MRE).
Results: We enrolled 130 patients between October 2016 and July 2019. For the diagnosis of moderate-to-severe steatosis (grade ≥ 2), the area under the receiver operating characteristic curve (AUROC) was lower in controlled attenuation parameter (0.69; 95% confidence interval [CI], 0.60-0.76) than MRI proton density fat fraction (0.82; 95% CI, 0.75-0.89; P = 0.008) and MR spectroscopy (0.83; 95% CI, 0.75-0.89; P = 0.006). For the diagnosis of advanced fibrosis (stage ≥ 3), the AUROC of MRE (0.89; 95% CI, 0.83-0.94) was superior compared with those of the Fibrosis-4 index (0.77; 95% CI, 0.69-0.84; P = 0.010), NAFLD fibrosis score (0.81; 95% CI, 0.73-0.87; P = 0.043), and transient elastography (0.82; 95% CI, 0.74-0.88; P = 0.062). For detecting advanced fibrosis or nonalcoholic steatohepatitis, the AUROC of MRE (0.86; 95% CI, 0.79-0.91) was higher than that of TE (0.76; 95% CI, 0.68-0.83) with statistical significance (P = 0.018).
Discussion: Multiparametric MR accurately identified a severe form of NAFLD. Multiparametric MR can be a valuable noninvasive method for evaluating the severity of NAFLD.
Cathcart J, Barrett R, Bowness J, Mukhopadhya A, Lynch R, Dillon J Liver Int. 2024; 45(4):e16127.
PMID: 39400428 PMC: 11891385. DOI: 10.1111/liv.16127.
Sex-specific associations in multiparametric 3 T MRI measurements in adult livers.
Liu C, Noda C, van der Geest R, Triaire B, Kassai Y, Bluemke D Abdom Radiol (NY). 2023; 48(10):3072-3078.
PMID: 37378865 DOI: 10.1007/s00261-023-03981-3.
Liang J, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J J Hepatol. 2023; 79(3):592-604.
PMID: 37121437 PMC: 10623141. DOI: 10.1016/j.jhep.2023.04.025.
Park H, Yoon E, Kim M, Lee J, Cho S, Won Jun D Front Med (Lausanne). 2022; 9:1024836.
PMID: 36405611 PMC: 9668872. DOI: 10.3389/fmed.2022.1024836.
Non-alcoholic fatty liver disease: A patient guideline.
Francque S, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus J JHEP Rep. 2021; 3(5):100322.
PMID: 34693236 PMC: 8514420. DOI: 10.1016/j.jhepr.2021.100322.